US-based Sagent Pharmaceuticals has introduced an antineoplastic agent ' Doxorubicin Hydrochloride Injection' in three vial presentations.
The injection has been used to produce regression in disseminated neoplastic conditions like acute lymphoblastic leukemia, acute myeloblastic leukemia, Wilms' tumor, neuroblastoma, soft tissue and bone sarcomas.
Other conditions include breast carcinoma and ovarian carcinoma, transitional cell bladder carcinoma, thyroid carcinoma, gastric carcinoma, Hodgkin's disease, malignant lymphoma and bronchogenic carcinoma in which the small cell histologic type is the most responsive compared to other cell types.
It is also indicated for use as a component of adjuvant therapy in women with evidence of axillary lymph node involvement following resection of primary breast cancer.
Along with all other products in the company's portfolio, Doxorubicin features Sagent's PreventIV Measures packaging and labeling, which is designed to help reduce medication errors.
The company is focused on developing, manufacturing, sourcing and marketing pharmaceutical products, with a specific emphasis on injectables.
